Back to School: How biopharma can reboot drug development. Access exclusive analysis here

China approves Solasia's oral mucositis product

Solasia Pharma K.K. (Tokyo:4597) said China's National Medical Products Administration

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE